Tonix Pharmaceuticals Holding Corp.

02/01/2023 | Press release | Distributed by Public on 02/01/2023 06:06

Tonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.